{"DataElement":{"publicId":"7801110","version":"1","preferredName":"Patient Cutaneous Melanoma Breslow Thickness Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation for questions relating to the diagnosis of cutaneous melanoma with breslow thickness as outlined in the study protocol.","longName":"BRESLOW","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"7801109","version":"1","preferredName":"Patient Cutaneous Melanoma Breslow Thickness Diagnosis Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma._The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI)_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:7802114v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7802114","version":"1","preferredName":"Cutaneous Melanoma Breslow Thickness Diagnosis Clinical Trial Eligibility Criteria","preferredDefinition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.:The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI):The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C3510:C25734:C15220:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Melanoma","conceptCode":"C3510","definition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Breslow Thickness","conceptCode":"C25734","definition":"The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4E94E-64F3-2341-E053-4EBD850AEC76","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5D2C93-DE54-0F6C-E053-4EBD850A96DE","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7801087","version":"1","preferredName":"Code Indicator","preferredDefinition":"A symbol or combination of symbols which is assigned to the members of a collection._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"7801087v1.0","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":"N/A","ValueMeaning":{"publicId":"2561784","version":"1","preferredName":"N/A","longName":"2561784","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE65-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-09","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C43B4-9CCB-4AC7-E053-4EBD850A927C","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"0","valueDescription":"No","ValueMeaning":{"publicId":"3216924","version":"1","preferredName":"No","longName":"3216924v1.00","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FB8B94D-C670-2CB0-E040-BB89AD4377A2","latestVersionIndicator":"Yes","beginDate":"2011-03-30","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2011-03-30","modifiedBy":"KUMMEROA","dateModified":"2022-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C43B4-9CDF-4AC7-E053-4EBD850A927C","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"},{"value":"1","valueDescription":"Yes","ValueMeaning":{"publicId":"6594241","version":"1","preferredName":"Yes","longName":"6594241v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3DC576-80CA-66DB-E053-F662850AEDCD","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-12-17","modifiedBy":"GDEEN","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF5C43B4-9CE9-4AC7-E053-4EBD850A927C","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208003","version":"1","preferredName":"Code Indicator","preferredDefinition":"A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25162:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3874-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C43B4-9CA9-4AC7-E053-4EBD850A927C","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. 10/27/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patients must have stage II p","type":"Preferred Question Text","description":"Patients must have stage II primary invasive cutaneous melanoma with Breslow thickness >2mm without ulceration, or >1mm with ulceration only (pT2b-pT4b, AJCC 8th edition) as determined by diagnostic biopsy (narrow excision, incision or punch biopsy) and subsequent histopathological analysis","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5CE68C-966B-16DB-E053-4EBD850ABC8E","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}